· Hong Kong Environmental Protection Department report shows the highest concentration of PM2.5 in Causeway Bay

· Hong Kong Environmental Protection Department report shows the highest concentration of PM2.5 in Causeway Bay

According to the Hong Kong Ming Pao Daily News, the Hong Kong Environmental Protection Agency's latest "Hong Kong Air Quality Report 2013" shows the average annual concentration of PM2.5 at three roadside air monitoring stations, with the highest in Causeway Bay, reaching 45 micrograms per cubic metre. The standard 35 micrograms exceeded 28.5%, and Central and Mong Kok recorded 34 and 33 micrograms respectively, which was close to exceeding the standard. The pollution varies greatly in different seasons. Take Causeway Bay as an example. From June to September last year, PM2.5 ranged from 28 to 35 micrograms; in December last year, it soared to 74 micrograms, exceeding 1.1 times.
In recent years, the Hong Kong Government has introduced a huge amount of public funds to replace the old commercial diesel vehicles. However, the roadside air quality has not improved significantly. The Secretary for the Environment of the University of Science and Technology, Mr Chan Siu-keung, believes that if the measures fail to achieve the expected results, the Government should also be accountable to the public. He said that the summer PM2.5 concentration is at a low level, but about half of the particles are still from local pollutants. If measures are taken to reduce emissions, the harsh conditions will be alleviated in the winter.

Larotrectinib Intermediates

Larotinib (Vitrakvi / Larotrectinib) is the first oral tyrosine kinase inhibitor approved for the treatment of NTRK gene fusion solid tumors. It is suitable for all types of solid tumors, regardless of their original location. NTRK gene fusion is a kind of chromosomal abnormality, which is formed when NTRK gene combines with another unrelated gene, and then translates and produces abnormal TRK protein.

Larotrectinib Intermediates,Larotrectinib Intermediates Cas 1218935-60-4,Intermediates Of Larotrectinib Cas 1218935-60-4,Cas1363380-51-1 Intermediates Of Larotrectinib

Jinan Guoding Pharmaceutical Co.,Ltd , https://www.jnguodingpharma.com